Adults with type 2 diabetes taking semaglutide had about 15% fewer bone fractures than adults taking other weight-loss medications, according to a retrospective analysis of health records from nearly 60,000 people, even though the semaglutide group lost more weight.
That last clause is what makes the finding notable. Substantial weight loss has generally been associated with bone loss, and concern that GLP-1 medications might weaken the skeleton has followed the drugs since they came into wide use.
